The next petition for consideration is PE1658, which was lodged by Wendy Stephen and is on compensation for people who suffered a neurological disability following administration of the Pluserix vaccine between 1988 and 1992. Members will recall that we were due to consider the petition at our meeting on 9 May but that, due to time constraints, we agreed to defer that consideration.
The petition calls for the Scottish Government to acknowledge and compensate people who suffered permanent neurological disabilities after having been administered with the Pluserix measles, mumps and rubella vaccine, which contained Urabe.
In its submission of 21 March this year, the Scottish Government acknowledged that some individuals who were affected by the vaccine might not meet the threshold for receiving a payment under the vaccine damage payment scheme. Although the Government makes clear that it sympathises with the individuals and their families, it notes that the issue of compensation under the scheme is a reserved matter. It adds that it does not have any plans to offer ex gratia payments.
The submission from the Department of Health and Social Care explains that the vaccine damage payment scheme provides a one-off tax-free lump-sum payment of £120,000. It also explains that the scheme was established to provide a measure of financial help in what it refers to as the “rare circumstances” in which it is established that vaccination was the cause of severe disability.
The submission also refers to the two legal tests that require to be passed: first, that the damage was caused by vaccination; and, secondly, that the disablement is 60 per cent or more, thereby making it severe disablement. That is assessed on the same basis as the industrial injuries disablement benefit scheme, which is a widely accepted test of disability.
In the petitioner’s submission of 28 April, she queries why the Scottish Government has
“not challenged Westminster’s insistence that vaccine damage claims be brought in England and nowhere else”.
She considers that it is unacceptable for individuals in Scotland who have been affected by the vaccine to be
“treated differently from other Scottish groups in similar circumstances, purely because the defective product was a vaccine”.
In her most recent submission, which is dated 3 June, the petitioner provides further historical context, referring to trials, chief medical officer circulars, published papers and MMR working group minutes over the period from 1987 to 1989. She considers that there remain a number of unanswered questions relating to the gathering, retention and accessibility of data from that period, which she asks the committee to pursue.
Do members have any comments or suggestions for action?
